Targeting invasive and angiogenic mechanisms in human glioblastoma
- Prosjektnummer
- 911991
- Ansvarlig person
- Hrvoje Miletic
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer, Neurological
- Forskningsaktivitet
- 1. Underpinning
The goal of the project is to identify new targets for brain tumor treatment. We are currently validating interesting candidates experimentally. At this stage "brukermedvirkning" is not relevant, but might become relevant when/if we enter the clinical phase of development. There is still a long way to go as we first need to verify candidates and then proceed with a DOFI to BTO. Then we can start to attract investors for drug development or think about drug repurposing strategies.
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Neuro Oncol 2018 05 18;20(6):743-752.
PMID: 29040782
The angiogenic switch leads to a metabolic shift in human glioblastoma.
Neuro Oncol 2017 03 01;19(3):383-393.
PMID: 27591677
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Neuro Oncol 2016 Dec;18(12):1644-1655. Epub 2016 jun 10
PMID: 27286795
- Thomas Daubon Prosjektdeltaker
- Hrvoje Miletic Prosjektleder
- Justin Vareecal Joseph Postdoktor
- Jian Wang Prosjektdeltaker
- Justin Vareecal Joseph Postdoktor
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest